Official websites use .gov
Secure .gov websites use HTTPS
Titles
- Network adequacy for behavioral health: existing standards and considerations for designing1
- Nevada Medicaid Fraud Control Unit: 2018 onsite inspection1
- New Hampshire Medicaid Fraud Control Unit: 2017 onsite review1
- New Jersey Medicaid Fraud Control Unit: 2017 onsite review1
- New Jersey could better ensure that nursing homes comply with federal requirements for life safety, emergency preparedness, and infection control1
- New Mexico Medicaid Fraud Control Unit: 2020 review1
- New York Medicaid Fraud Control Unit: 2017 onsite inspection1
- New York did not ensure that a managed care organization complied with requirements for denying prior authorization requests1
- Newborn health: federal action needed to address neonatal abstinence syndrome : report to Congressional addressees1
- Next steps: improving the Medicaid buy-in for workers with disabilities1
- No free lunch?: current challenges facing National School Lunch and School Breakfast Programs1
- Non-clinical and clinical investigation of devices used for the treatment of benign prostatic hyperplasia (BPH): guidance for industry and Food and Drug Administration staff1
- Non-clinical performance assessment of tissue containment systems used during power morcellation procedures: guidance for industry and Food and Drug Administration staff1
- Nonallergic rhinitis: developing drug products for treatment1
- Nonclinical considerations for mitigating nonhuman primate supply constraints arising from the COVID-19 pandemic1
- Nonclinical evaluation of the immunotoxic potential of pharmaceuticals: guidance for industry1
- Nonclinical testing of orally inhaled nicotine-containing drug products1
- Nonmetastatic castration-resistant prostate cancer: considerations for metastasis-free survival endpoint in clinical trials1
- Nontuberculous mycobacterial pulmonary disease caused by mycobacterium avium complex: developing drugs for treatment : guidance for industry1
- Notifying CDRH of a permanent discontinuance or interruption in manufacturing of a device under Section 506J of the FD&C Act during the COVID-19 public health emergency (revised): guidance for industry and Food and Drug Administration staff1